Actively Recruiting
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
Led by Shanghai Zhongshan Hospital · Updated on 2026-03-12
2846
Participants Needed
1
Research Sites
188 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The OPTION2 trial (randomized controlled trial of IndObufen versus asPirin after coronary drug-eluting stent implantaTION in elderly patients with acute coronary syndrome) was designed to compare the 1-year clinical efficacy and safety of indobufen-based dual antiplatelet therapy (DAPT) (indobufen 100mg bid plus ticagrelor 90mg bid) or conventional DAPT (aspirin 100mg qd plus ticagrelor 90mg bid) in acute coronary syndrome (ACS) patients aged over 65 years old undergoing coronary drug-eluting stent (DES) implantation.
CONDITIONS
Official Title
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 65 years old
- Diagnosed with acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction)
- Treated with at least one drug-eluting stent implanted in the coronary lesion
- Receiving dual antiplatelet therapy including aspirin plus ticagrelor
- Agree to participate in the trial
You will not qualify if you...
- Elective surgical procedure planned within 12 months
- Life expectancy of 1 year or less
- Known allergy or intolerance to aspirin, ticagrelor, or nonsteroidal anti-inflammatory drugs (NSAIDs)
- History of cerebral hemorrhage
- History of stroke within the past six months
- Active bleeding
- Known significant blood disorders
- Clinically important low platelet count (less than 100 x 10^9/L) or anemia (less than 90 g/L)
- Active cancer
- Using oral anticoagulants
- Currently participating in another clinical study
- Other conditions considered unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
L
Lili Xu, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here